These results may indicate extra considerations in choosing a cancer therapy in addition to the treatment of the BRAF mutation that exists in 42/48 (one of the 49 cell lines used in this study lacks analysis) of the CCLE cell lines across all clusters (Ghandi et al., 2019). The gene discussed is BRAF; the disease is cancer.